FDA approves Fotivda for relapsed or refractory advanced renal cell carcinoma

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

July 19, 2024

Vol.50 No.29

By Jacquelyn Cobb

A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital

When air sirens sound over Kyiv, Ukraine, patients undergoing bone marrow transplants at Ohmatdyt National Children’s Hospital don’t have the option of going to the bomb shelter.

July 19, 2024

Vol.50 No.29

By Paul Goldberg

U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access

In a change in methodology, U.S. News & World Report has integrated Medicare Advantage data into the analyses for patient outcomes, creating a shift in rankings for specialties that include oncology.

July 19, 2024

Vol.50 No.29

By Matthew Bin Han Ong

Health Equity White House

Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa

Source: Livestream of White House Africa Cancer Care ForumThe White House Cancer Moonshot is committing an additional $100 million to programs focused on reducing cancer burden in African countries.

July 19, 2024

Vol.50 No.29

By McKenzie Prillaman

Health Equity

Proposed rule by CMS would expand access to cancer treatment at tribal facilities

The Centers for Medicare and Medicaid Services said it intends to start providing additional reimbursement for some high-cost drugs for people with Medicare who receive care at Indian Health Service or tribal hospitals, beginning Jan. 1, 2025.

Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute

Robert C. Gallo joined Tampa General Hospital on July 8 as founder and director of the Microbial Oncology Program at the TGH Cancer Institute and senior scientific advisor to the executive director of the TGH Cancer Institute.

July 19, 2024

Vol.50 No.29

FDA approves Fotivda for relapsed or refractory advanced renal cell carcinoma

YOU MAY BE INTERESTED IN

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital

U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access

Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa

Proposed rule by CMS would expand access to cancer treatment at tribal facilities

Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute

Renew today!

Subscriber content

Login

FDA approves Fotivda for relapsed or refractory advanced renal cell carcinoma

YOU MAY BE INTERESTED IN

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

A view from the BMT unit on the day a Russian cruise missile hit Kyiv’s Ohmatdyt hospital

U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage dataRankings now include a list of Best Regional Hospitals for Equitable Access

Cancer Moonshot contributes additional $100M to reduce cancer burden in Africa

Proposed rule by CMS would expand access to cancer treatment at tribal facilities

Robert Gallo named founding director of Microbial Oncology Program at TGH Cancer Institute

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

U.S. News rankings for cancer hospitals shift again with inclusion of Medicare Advantage data
Rankings now include a list of Best Regional Hospitals for Equitable Access